RBC Capital Markets upgraded CRH Medical (TSX:CRH; NYSE MKT:CRHM) to “outperform” from “sector perform” but lowered its price target to $6 (Canadian) from $8.50. The stock closed at $4.07 on July 20.Read More
RBC Capital Markets initiated coverage of TSO3 (TSX:TOS) with an “outperform, speculative risk” rating and $4.25 (Canadian) price target. The stock closed at $3.09 on May 2.Read More
RBC Capital Markets downgraded Concordia International (NASDAQ:CXRX; TSX:CXR) to “underperform” from “sector perform” and cut its price target to $1 from $2.50. The stock closed at $2.38 on Dec. 6.Read More
RBC Capital Markets initiated coverage of CRH Medical (NYSE MKT:CRHM; TSX:CRH) with an “outperform” rating and price target of $6.50 (Canadian). The stock closed at $5.50 on Wednesday.
Analyst Doug Miehm writes that CRH has leveraged its long-standing GI physician relationships and expertise to acquire anesthesiology service businesses in the GI space.Read More